Title
A novel locus (RP24) for X-linked retinitis pigmentosa maps to Xq26-27
Date Issued
01 January 1998
Access level
open access
Resource Type
journal article
Author(s)
Gieser L.
Göring H.
Ott J.
Hoffman D.
Cideciyan A.
Birch D.
Jacobson S.
Swaroop A.
Publisher(s)
University of Chicago Press
Abstract
Two genetic loci, RP2 and RP3, for X-linked retinitis pigmentosa (XLRP) have been localized to Xp11.3-11.23 and Xp21.1, respectively. RP3 appears to account for 70% of XLRP families; however, mutations in the RPGR gene (isolated from the RP3 region) are identified in only 20% of affected families. Close location of XLRP loci at Xp and a lack of unambiguous clinical criteria do not permit assignment of genetic subtype in a majority of XLRP families; nonetheless, in some pedigrees, both RP2 and RP3 could be excluded as the causative locus. We report the mapping of a novel locus, RP24, by haplotype and linkage analysis of a single XLRP pedigree. The RP24 locus was identified at Xq26-27 by genotyping 52 microsatellite markers spanning the entire X chromosome. A maximum LOD score of 4.21 was obtained with DXS8106. Haplotype analysis assigned RP24 within a 23-cM region between the DXS8094 (proximal) and DXS8043 (distal) markers. Other chromosomal regions and known XLRP loci were excluded by obligate recombination events between markers in those regions and the disease locus. Hemizygotes from the RP24 family have early onset of rod photoreceptor dysfunction; cone receptor function is normal at first, but there is progressive loss. Patients at advanced stages show little or no detectable rod or cone function and have clinical hallmarks of typical RP. Mapping of the RP24 locus expands our understanding of the genetic heterogeneity in XLRP and will assist in development of better tools for diagnosis.
Start page
1439
End page
1447
Volume
63
Issue
5
Language
English
OCDE Knowledge area
Genética humana
DOI
Scopus EID
2-s2.0-0032231868
PubMed ID
Source
American Journal of Human Genetics
ISSN of the container
00029297
Sponsor(s)
We are grateful to D. Hanna, L. Gardner, J. Christopher, K. Mejia, and H. Heo for help with the study; to Y. Huang and K. Zhao for data analyses; and to D. Giebel for assistance in preparing the manuscript. This research was supported by grants from the National Institutes of Health (EY07961 to A.S., EY05627 to S.G.J., EY05235 to D.G.B., and HG00008 to J.O.), the Foundation Fighting Blindness (to A.S., A.V.C., D.G.B., D.R.H., J.O., and S.G.J.), the Chatlos Foundation, Inc. (to S.G.J.), the Food and Drug Administration (to D.R.H.), the Kirby Foundation (to S.G.J), the Mackall Trust (to S.G.J.), the Whitaker Foundation (to A.V.C.), and by unrestricted departmental support from Research to Prevent Blindness. We also acknowledge National Institutes of Health grants EY07003 (Core) and M01-RR00042 (General Clinical Research Center) and a Shared Equipment grant from the Office of the Vice President for Research, University of Michigan. A.S. is the recipient of a Research to Prevent Blindness Lew R. Wasserman Merit Award.
Sources of information:
Directorio de Producción Científica
Scopus